
John P Mueller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2092418/publications.pdf Version: 2024-02-01



IOHN P MUELLER

#	Article	IF	CITATIONS
1	ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nature Microbiology, 2017, 2, 17104.	13.3	187
2	Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea. New England Journal of Medicine, 2018, 379, 1835-1845.	27.0	148
3	Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. Scientific Reports, 2015, 5, 11827.	3.3	85
4	Characterization of the Novel DNA Gyrase Inhibitor AZD0914: Low Resistance Potential and Lack of Cross-Resistance in Neisseria gonorrhoeae. Antimicrobial Agents and Chemotherapy, 2015, 59, 1478-1486.	3.2	74
5	Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of <i>Neisseria gonorrheae</i> , Including Multi-Drug-Resistant Isolates. ACS Infectious Diseases, 2020, 6, 1332-1345.	3.8	73
6	<i>In Vitro</i> Antibacterial Activity of AZD0914, a New Spiropyrimidinetrione DNA Gyrase/Topoisomerase Inhibitor with Potent Activity against Gram-Positive, Fastidious Gram-Negative, and Atypical Bacteria. Antimicrobial Agents and Chemotherapy, 2015, 59, 467-474.	3.2	67
7	High <i>In Vitro</i> Activity of the Novel Spiropyrimidinetrione AZD0914, a DNA Gyrase Inhibitor, against Multidrug-Resistant Neisseria gonorrhoeae Isolates Suggests a New Effective Option for Oral Treatment of Gonorrhea. Antimicrobial Agents and Chemotherapy, 2014, 58, 5585-5588.	3.2	62
8	Discovery of Novel DNA Gyrase Inhibiting Spiropyrimidinetriones: Benzisoxazole Fusion with N-Linked Oxazolidinone Substituents Leading to a Clinical Candidate (ETX0914). Journal of Medicinal Chemistry, 2015, 58, 6264-6282.	6.4	60
9	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases. Journal of Medicinal Chemistry, 2020, 63, 12511-12525.	6.4	44
10	Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914. Journal of Biological Chemistry, 2015, 290, 20984-20994.	3.4	34
11	Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914). Antimicrobial Agents and Chemotherapy, 2016, 60, 621-623.	3.2	26
12	<i>In Vitro</i> Characterization of ETX1317, a Broad-Spectrum β-Lactamase Inhibitor That Restores and Enhances β-Lactam Activity against Multi-Drug-Resistant <i>Enterobacteriales</i> , Including Carbapenem-Resistant Strains. ACS Infectious Diseases, 2020, 6, 1389-1397.	3.8	25
13	In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrione. International Journal of Antimicrobial Agents, 2016, 48, 328-330.	2.5	17
14	Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	15
15	Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282. ACS Infectious Diseases, 2020, 6, 1378-1388.	3.8	13
16	Challenges and opportunities in the discovery, development, and commercialization of pathogen-targeted antibiotics. Drug Discovery Today, 2021, 26, 2084-2089.	6.4	10
17	Determination of MIC Quality Control Ranges for the Novel Gyrase Inhibitor Zoliflodacin. Journal of Clinical Microbiology, 2019, 57, .	3.9	7
18	Thorough QT Study To Evaluate the Effect of Zoliflodacin, a Novel Therapeutic for Gonorrhea, on Cardiac Repolarization in Healthy Adults. Antimicrobial Agents and Chemotherapy, 2021, 65, e0129221.	3.2	5

#	Article	IF	CITATIONS
19	Human Pharmacokinetics and Dose Projection of ETX2514/Sulbactam Combination for Use in the Treatment of Infections Caused by Acinetobacter baumannii. Open Forum Infectious Diseases, 2016, 3, .	0.9	1